LAS VEGAS, NV — January 02, 2019 – Digipath, Inc. (OTCQB:DIGP), a service oriented independent testing laboratory, data acquisition and media firm focused on the developing cannabis and hemp markets, is pleased to announce its plans to expand internationally. Colombia is the first foreign market in which Digipath plans to provide cannabis testing for both local consumers and cannabis exporters. Colombia is projected to be a significant cannabis exporter due to its climate and low cost of production and all cannabis products will need to be tested for potency and safety prior to export to any other country.
Colombia formally legalized medical marijuana in 2015. The country has realigned its interests to the export market in its current policy operations and is preparing to produce 40.5 tons of cannabis per year, starting in 2019.
Digipath has retained legal representation in Colombia, hired a local operations manager and is evaluating potential locations. “Clearly, international expansion presents a tremendous opportunity for Digipath and its shareholders,” stated Todd Denkin, CEO, Digipath, Inc. “A fully-realized presence in South America could significantly increase our customer base. We expect Colombia to be one of the market leaders in cannabis, hemp and CBD production and are excited about the possibilities.”
Through Digipath’s Chief Science Officer Dr. Cindy Orser’s work in Nevada, Digipath Labs helped pioneer cannabis lab testing protocols and implement one of the nation’s most stringent cannabis safety regulations. This commitment to excellence has now positioned Digipath Labs as a market leader in the cannabis lab testing industry. The Company intends to carry the testing standards it has developed and proven in Nevada into these new international markets.
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
TNM News Corp. is not an investment advisor, we have no access to non-public information about publicly traded companies, and this is not a place for the giving or receiving of financial advice, advice concerning investment decisions or tax or legal advice. We are not regulated by the Financial Services Authority.
We are an educational forum for analyzing, learning & discussing general and generic information related to stocks, investments and strategies. No content on the site constitutes – or should be understood as constituting – a recommendation to enter in any securities transactions or to engage in any of the investment strategies presented in our site content. We do not provide personalized recommendations or views as to whether a stock or investment approach is suited to the financial needs of a specific individual.
